Trial Profile
Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis - Extension Study - [EXTENSION OF 700196582]
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 27 Apr 2018
Price :
$35
*
At a glance
- Drugs Alogliptin (Primary)
- Indications Cardiovascular disorders; Cerebrovascular disorders; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SPEAD-A Extension
- 23 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 30 Apr 2013 New trial record